T-type voltage-dependent calcium channels may play an important role in synaptic plasticity, but lack of specific antagonists has hampered investigation into this possible function. We investigated the role of the T-type channel in a canonical model of in-vivo cortical plasticity triggered by monocular deprivation. We identified a compound (TTA-I1) with subnanomolar potency in standard voltage clamp assays and high selectivity for the T-type channel. When infused intracortically, TTA-I1 reduced cortical plasticity triggered by monocular deprivation while preserving normal visual response properties. These results show that the T-type calcium channel plays a central role in cortical plasticity.
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Victor N. Unlike most VDCCs that allow extracellular calcium into neurons after activation by membrane depolarization (e.g. high-voltage activated), T types are inactivated at resting membrane potentials and become 'de-inactivated' only after a period of membrane hyperpolarization. Small depolarizations then open the channel giving rise to a calcium-mediated low-threshold spike that drives burst firing in neurons [1] .
The function of the T-type channel is not completely understood, but it may be important in synaptic plasticity. T-type channels are enriched in the neocortex and thalamus and are highly concentrated in dendrites [1] . They may also mediate several types of in-vitro plasticity [2] . The precise contribution of T-type channels to synaptic plasticity is, however, unclear because available antagonists inhibit other VDCCs or strongly influence other ion channels [3] .
We investigated the role of the T-type channel in a classic model of cortical plasticity in vivo. Monocular deprivation (MD) during a critical period of development causes a rapid remodeling of the visual cortex in favor of the nondeprived eye; a process known as ocular dominance plasticity [4] . We determined the effects of selective T-type channel antagonism on ocular dominance plasticity by infusing the visual cortex with a newly identified T-type antagonist with subnanomolar potency (TTA-I1).
Methods

In-vitro identification and screening of a novel T-type antagonist
An in-vitro screening protocol [5] identified a potent [5] [6] [7] . We then tested TTA-I1 for functional inhibition of CACNA1G, CACNA1H, CACNA1C [8] , CACNA1A, CACNA1B, and CACNA1E calcium channels [9] , as well as an array of additional targets in functional and binding assays at MDS Pharma Services according to standard protocols (http://www.mdsps.com). Assuming off target activity would most likely occur at other ion channels, targets were chosen on the basis of available ion channel assays.
Electrophysiological verification
Whole-cell patch-clamp recordings on HEK-293 cells expressing human CACNA1G, CACNA1H, CACNA1I, or CACNA1C calcium channels [8] were carried out at room temperature. Currents were recorded and analyzed using equipment and software similar to that described earlier [8] . Nine cats were prepared for cranial surgeries during the critical period as described earlier [10] . A craniotomy was made over primary visual cortex and a 30-gauge cannula (Durect Corporation, Cupertino California, USA) was positioned in the visual cortex and anchored with two to three bone screws and dental acrylic. The cannula was attached to a 2ML2 Alzet osmotic minipump (Durect Corporation) placed subcutaneously. Each visual hemisphere was implanted with pumps either delivering vehicle (n=4, 50% DMSO, 50% artificial cerebrospinal fluid) or 5 mM (n=1) or 50 mM (n=4) TTA-I1 in vehicle. The pumps were presoaked in warm, sterile saline before surgery to ensure that infusion began immediately after implantation (pumping rate: 5 ml/h; pump duration: 14-16 days). All cats were treated with antibiotics and analgesics [10] . Once the animals had recovered, they were returned to their home cages for up to 11 days at which time they were anesthetized with isoflorane gas and had one eye sutured shut. They were again returned to their cages and the eye remained closed for 2-3 days [11] . Five cats of comparable age (mean ± SEM: 35.8 ± 1.46 days), but with no MD were also analyzed to provide normative comparison data (data from three cats reproduced with permission from Jha et al. [10] ).
Microelectrode recordings in visual cortex
The nine cats undergoing MD and the normally sighted cats were prepared for microelectrode recordings and analyses as described earlier [10] . After the assignment of ocular dominance ranks for each neuron, scalar measures of plasticity and visual response properties (orientation selectivity, signal-to-noise) were calculated [10, 12] . Three vehicles and two TTA-I1 hemispheres were excluded from analyses because the infusion tubing was damaged. Parametric data were assessed with one-way analyses of variance (ANOVAs), nonparametric data were assessed with nonparametric ANOVAs (Kruskal-Wallis or Friedman on ranks); significant main effects were further evaluated with Student-Newman-Keuls (SNK) post-hoc tests.
Additional in-vivo control experiments
To determine whether TTA-I1 by itself disrupted visual processing in normally sighted animals, two additional cats were implanted with minipumps containing either 50 mM TTA-I1 (placed in the right visual cortex) or vehicle (placed in the left visual cortex). At the end of the infusion period, the cats were prepared for microelectrode recording of visual responses (age at assay: 38 and 39 days). After an initial sampling of single neuronal responses in the TTA-I1-infused hemispheres, we examined the acute effects of TTA-I1 in the vehicleinfused hemispheres using protocols comparable to those used by previous investigators [13] . Visual response properties were computed and analyzed using a repeatedmeasure ANOVA for nonparametric data, followed by SNK post-hoc tests where appropriate. All animal procedures were approved by animal care (Institutional Animal Care and Use) committee of the University of Pennsylvania.
Results
In-vitro screening of TTA-I1
The results of our in-vitro screening and testing of TTA-I1 are shown in Fig. 1 (Fig. 1a) . The observed signal reflects calcium flux through the channel because the signal is dependent on tetracycline-induced expression, is independent of osmotic effects and the magnitude of the signal is dependent on the calcium concentration gradient between the wash solution and stimulus conditions.
The fluorescent imaging plate reader (FLIPR) assay identified TTA-I1 as a T-type antagonist with a potency of 31.9 nM (n=60). As a reference standard, the potency of mibefradil was 127.4 nM (n=3; Fig. 1b) , consistent with reported values in similar assays [14, 15] . These potency values, derived from a fit to all data, differ from the average potencies determined from independent runs by less than 10%. The state-dependent properties of TTA-I1 were characterized by voltage-clamp assays (Fig. 1c) . Comparison of potencies determined at membrane holding potentials of -80 and -100 mV confirmed that TTA-I1 is a state-independent antagonist with potencies of 0.7 and 0.8 nM, respectively. Similar experiments with cells expressing CACNA1G (0.4 and 1.4 nM) and CACNA1H (3 and 2 nM) showed that TTA-I1 is a pan-T-type antagonist (data not shown).
Several additional assays showed that TTA-I1 had minimal antagonist activity at other calcium or ion channels. FLIPR-based calcium flux assays (as described in Ref. [9] ) showed the half maximal inhibitory concentration values greater than 10 mM for CACNA1A, CACNA1B, and CACNA1E channels. Standard voltage-clamp assays showed that TTA-I1 had greater than 12 000-fold selectivity for T-type over L-type calcium channels (Fig. 1d) . TTA-I1 was further screened in a panel of binding assays as summarized in Table 1 , which also showed high selectivity for T-type calcium channels versus other ion channels.
The effects of TTA-I1 on ocular dominance plasticity Electrophysiological recordings were made in 477 neurons from seven TTA-I1-infused hemispheres (mean ± SEM age at MD: 35.75 ± 1.93 days), 314 neurons from five vehicle hemispheres (37.25 ± 0.25 days), and 665 neurons from nine normal hemispheres (mean ± SEM age at assay: 36.57 ± 1.5 days). The mean ± SEM days of infusion (and MD) were: TTA-I1, 10 ± 0.41 (2.25 ± 0.25) and vehicle, 9 ± 0.82 (2.25 ± 0.25).
The results of our in-vivo measurements are shown in Fig. 2 . TTA-I1 inhibited plasticity without producing abnormal visual response properties. A slight difference was found in the number of visually unresponsive neurons in TTA-I1 cortices (1.9%) relative to vehicle-infused cortices (0.6%), but no differences in orientation selectivity or signalto-noise (deprived eye or nondeprived eye ANOVAs, NS) between the groups (data not shown). An elevation was observed in nondeprived eye firing in vehicle-infused neurons at the preferred orientation compared with TTA-I1 and normal (10.9 ± 1.6 vs. 5.1 ± 1, 6.2 ± 1.3 Hz: ANOVA, F=4.6, P < 0.022, SNK P < 0.05) but no differences in mean firing between TTA-I1 and normal (SNK, NS) or between the groups in deprived eye firing at the preferred orientation (ANOVA, NS).
Nonspecific effects of TTA-I1, chronic and acute measurements TTA-I1 had no significant effects on peak-firing rates, orientation selectivity or signal-to-noise in visual cortical neurons from normally sighted cats (ANOVA, NS, data not shown). Scalar measures of ocular dominance in TTA-I1-infused hemispheres were also within normative values for cats with binocular vision (n=89 neurons, mean ± SEM CBI: 0.53 ± 0.14; MI: 0.38 ± 0.07, n=2).
Acute application of TTA-I1 also failed to significantly alter basic visual response properties, even after 30 min of continuous application (Fig. 2b and c) . This was evaluated in nine visual cortical neurons (four from cat 1, five from cat 2). For example, TTA-I1 had no significant effects on orientation selectivity as shown in two representative neurons (Fig. 2b) ; nor were there any significant effects in any visual response property relative to vehicle in group means (repeated measure ANOVA, NS: all measures).
Discussion
We used a high-throughput FLIPR screen to identify a compound with subnanomolar potency and high selectivity for T-type channels. When infused intracortically, TTA-I1-reduced plasticity while leaving other neuronal response properties intact. The suppression of plasticity is not because of abnormalities in cortical function because TTA-I1 does not produce unresponsive cortex or gross alterations in visual responses as reported with other drugs [16] . TTA-I1 also had no significant effects on visual response properties either when combined with MD or in cats with normal binocular vision. Our results are also probably not caused by TTA-Il action at other VDCCs or other neurotransmitter receptors. TTA-I1 had greater than 12 000-fold selectivity for T-type over L-type calcium channels with negligible functional effect on other high-voltage activated calcium channels or displacement of radioligands for g-aminobutyric acid (GABA) and glutamate receptors at micromolar concentrations in vitro. Micromolar concentrations of TTA-I1 inhibited binding to K A , K V , hERG potassium channels and the 5-HT1 receptor to varying degrees ( Table 1) . The concentration of an agent used in in-vitro assays, however, must be scaled up by several orders of magnitude to maintain equivalent concentrations in vivo [16] . Therefore, millimolar concentrations of TTA-I1 would be required to produce comparable inhibition of these channels and receptors in vivo. Nor can our results be ascribed to partial 5-HT1 antagonism, because intracortical infusion of a broad spectrum 5-HT1 antagonist does not inhibit ocular dominance plasticity [17] .
A most likely explanation of our results is that T-type channels influence cortical plasticity by altering neuronal excitability and/or by providing a calcium signal necessary for synaptic remodeling. T-type channels are enriched in dendrites [18] where they modulate burst discharges and the propagation of excitation from distal to proximal neuronal sites [1, 19] . Depending on their dendritic concentration, they may gate levels of calcium sufficient to trigger either long-term potentiation or long-term depression [1, 19] and possibly gene transcription [20, 21] . In addition, T-type channels are located in GABAergic cells [18] , subsets of which are critical for ocular dominance plasticity [22] . If present in these subtypes, they may powerfully modulate GABAergic input onto pyramidal neurons. A final intriguing possibility is that T-type channels may regulate sleep-dependent changes in cortical circuits. Sleep enhances ocular dominance plasticity through unknown activity-dependent mechanisms [10] . The kinetics of the T-type channel make it an especially attractive candidate source of extracellular calcium during slow-wave sleep as this brain state is characterized by sustained neuronal hyperpolarization and low-threshold spike-mediated oscillations [23] .
Conclusion
The function of T-type calcium channels in the central nervous system is unknown. We now show that these VDCCs may play a critical role in synaptic plasticity. T-type-dependent plasticity Uebele et al. 261
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